Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: Current status and new directions

Clinical Lung Cancer

Volumn 9, Issue SUPPL. 3, 2008, Pages

  Gautschi, Oliver ^a   Mack, Philip C ^b   Davies, Angela M ^b   Jablons, David M ^c,e   Rosell, Rafael ^d   Gandara, David R ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimicrotubule agents; BRCA1; Carboplatin; ERCC1; Gemcitabine; RRM1; Xeroderma pigmentosa

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOCETAXEL; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 2; NAVELBINE; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISEASE MARKER; DNA SYNTHESIS; DRUG SENSITIVITY; EXCISION REPAIR; FEBRILE NEUTROPENIA; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 62349084806     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.s.019     Document Type: Article

References (65)

1. Chen H-Y, Yu S-L, Chen C-H, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356:11-20.
2. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer [published correction appears in N Engl J Med 2007; 356:201-2.]. N Engl J Med 2006; 355:570-80.
3. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25:587-95.
4. Goodman LS, Wintrobe MM, Dameshek W, et al. Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA 1984; 251:2255-61.
5. Rosenberg B. Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry. Cancer Treat Rep 1979; 63:1433-8.
6. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1:22-33.
7. Britten RA, Liu D, Tessier A, et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000; 89:453-7.
8. Dabholkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94:703-8.
9. Lee KB, Parker RJ, Bohr V, et al. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcino-genesis 1993;14:2177-80.
10. Chang I-Y, Kim M-H, Kim HB, et al. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005; 327:225-33.
11. Larminat F, Bohr VA. Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res 1994; 22:3005-10.
12. Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998; 78(Suppl 3):1-7.
13. Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribo- nucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64:3761-6.
14. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry 1981; 20:3247-52.
15. Noble RL. The discovery of the vinca alkaloids--chemotherapeutic agents against cancer. Biochem Cell Biol 1990; 68:1344-51.
16. Meresse P, Dechaux E, Monneret C, et al. Etoposide: discovery and medicinal chemistry. Curr Med Chem 2004; 11:2443-66.
17. Shih C, Habeck LL, Mendelsohn LG, et al. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998; 38:135-52.
18. Kelly K, Crowley J, Bunn PA, Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-8.
19. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
20. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-91.
21. Gautschi O, Mack P, Heighway J, et al. Cellular and molecular biology of lung cancer as the basis for targeted therapy. New York, NY: Taylor and Francis; 2007.
22. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-44.
23. Johnston PG, Lenz H-J, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407-12.
24. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356:800-8.
25. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005; 127:978-83.
26. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:1878-85.
27. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small- cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-91.
28. Filipits M, Haddad V, Schmid K, et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 2007; 13:3892-8.
29. Sève P, Lai R, Ding K, et al. Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007; 13:994-9.
30. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007; 2:e1129.
31. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-91.
32. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17:1818-25.
33. Wachters FM, Wong LSM, Timens W, et al. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005; 50:211-9.
34. Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007; 98:1336-43.
35. Booton R, Ward T, Ashcroft L, et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007; 2:902-6.
36. Fujii T, Toyooka S, Ichimura K, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer; September 28, 2007 [e-pub ahead of print].
37. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10:1318-25.
38. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25:2747-54.
39. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24:4731-7.
40. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:2741-6.
41. Filipits M, Pirker R, Dunant A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007; 25:2735-40.
42. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gem- citabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10(12 Pt 2):4215s-9s.
43. Simon GR, Williams CC, Chiappori AA, et al. Molecular analysis-directed individualized therapy (MADeIT) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):385s (Abstract 7502).
44. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16:309-16.
45. Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for non-small cell lung cancer-how to handle stage I disease. Oncologist 2007; 12:331-7.
46. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-60.
47. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc Am Soc Clin Oncol 2004; 22(14 suppl):621a (Abstract 7019).
48. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006; 24(18 suppl):365s (Abstract 7007).
49. Bepler G. Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720. Clin Lung Cancer 2007; 8:509-11.
50. Ishihara S, Minato K, Hoshino H, et al. The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohis- tochemical evaluation using biopsy specimens. Lung Cancer 1999; 26:187-94.
51. Sève P, Isaac S, Trédan O, et al. Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine- based chemotherapy. Clin Cancer Res 2005; 11:5481-6.
52. Sève P, Mackey J, Isaac S, et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4:2001-7.
53. Kamath K, Wilson L, Cabral F, et al. βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005; 280:12902-7.
54. Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al. Molecular pathologic substag- ing in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998; 16:2468-77.
55. Mack PC, Galvin IV, Kimura T, et al. Molecular abnormalities of DNA damage and anti-microtubule response pathways in non-small cell lung carcinomas (NSCLC) from patients on the Southwest Oncology Group (SWOG) 9509 trial. Proc Am Soc Clin Oncol 2003; 22:639 (Abstract 2569).
56. Hsu DS, Balakumaran BS, Acharya CR, et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 2007; 25:4350-7.
57. Acharya C, Hsu D, Balakumaran B, et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced non- small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):385s (Abstract 7501).
58. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22:2594-601.
59. Gautschi O, Hugli B, Ziegler A, et al. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum- based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006; 51:303-11.
60. Sekine I, Nokihara H, Yamamoto N, et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer 2006; 53:157-64.
61. Gandara DR, Kawaguchi T, Crowley JJ, et al. Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): a model for testing population-related pharmacogenomics. J Clin Oncol 2007; 25(18 suppl):385s (Abstract 7500).
62. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004; 22:4157-64.
63. Gautschi O, Huegli B, Ziegler A, et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 2007; 254:265-73.
64. Kimura T, Holland WS, Kawaguchi T, et al. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann N Y Acad Sci 2004; 1022:55-60.
65. Ramirez JL, Rosell R, Taron M, et al. 14-3-3σ methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: the Spanish Lung Cancer Group. J Clin Oncol 2005; 23:9105-12.